{"coredata": {"prism:url": "https://api.elsevier.com/content/article/pii/S0151963817310645", "dc:identifier": "doi:10.1016/S0151-9638(17)31064-5", "eid": "1-s2.0-S0151963817310645", "prism:doi": "10.1016/S0151-9638(17)31064-5", "pii": "S0151-9638(17)31064-5", "dc:title": "Quoi de neuf en oncodermatologie ? ", "prism:publicationName": "Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie", "prism:aggregationType": "Journal", "prism:issn": "01519638", "prism:volume": "144", "prism:startingPage": "IVS40", "prism:endingPage": "IVS46", "prism:pageRange": "IVS40-IVS46", "dc:format": "application/json", "prism:coverDate": "2017-12-31", "prism:coverDisplayDate": "December 2017", "prism:copyright": "Copyright \u00a9 2017 Elsevier Masson SAS. All rights reserved.", "prism:publisher": "Elsevier Masson SAS.", "prism:issueName": "Quoi de neuf en 2017 ?- Journ\u00e9es Dermatologiques de Paris", "dc:creator": [{"@_fa": "true", "$": "Lebb\u00e9, C."}], "dc:description": "\n               R\u00e9sum\u00e9\n               \n                  Ce \u00ab Quoi de neuf en oncodermatologie ? \u00bb aborde les nouveaut\u00e9s 2017 sur l\u2019\u00e9pid\u00e9miologie et la prise en charge des cancers cutan\u00e9s. On retiendra l\u2019augmentation constante des carcinomes, les facteurs de risque du carcinome \u00e9pidermo\u00efde, notamment chez les greff\u00e9s o\u00f9 la mortalit\u00e9 li\u00e9e aux cancers cutan\u00e9s est importante. Nouveaut\u00e9s \u00e9pid\u00e9miologiques sur le m\u00e9lanome : augmentation de la mortalit\u00e9 malgr\u00e9 le d\u00e9pistage, exposition professionnelle aux UV, second m\u00e9lanome et risque plus \u00e9lev\u00e9 apr\u00e8s survenue d\u2019un carcinome. On doit tenir compte des nouvelles classifications: AJCC8 pour le m\u00e9lanome et les carcinomes. L\u2019intelligence artificielle pourrait rapidement modifier les pratiques de d\u00e9pistage des cancers cutan\u00e9s gr\u00e2ce au deep learning.\n                  Pour le ganglion sentinelle, plus d\u2019int\u00e9r\u00eat au curage syst\u00e9matique qui n\u2019am\u00e9liore pas la survie. La radioth\u00e9rapie est essentielle au pronostic du carcinome de Merkel et la chirurgie de Mohs peut \u00eatre int\u00e9ressante. Dans le m\u00e9lanome m\u00e9tastatique, multiples r\u00e9sultats sur l\u2019immunoth\u00e9rapie et les traitements cibl\u00e9s : dur\u00e9e, dose, combinaisons, \u00e9tude des m\u00e9canismes de r\u00e9sistances. La grande nouveaut\u00e9 est l\u2019immunoth\u00e9rapie ou le traitement cibl\u00e9 comme adjuvant, donnant une am\u00e9lioration de survie sans rechute.\n               \n            \n               Summary\n               \n                  This \u2018What\u2019s new in oncodermatology?\u2019 addresses the developments in 2017 on the epidemiology and management of skin cancers. We observe a constant increase in carcinomas, risk factors for squamous cell carcinoma, especially in transplant recipients where skin cancer mortality is important. Among epidemiological developments in melanoma are increased mortality despite screening, occupational exposure to UV, second melanoma and higher risk after carcinoma. New classifications that should be considered are AJCC8 for melanoma and carcinoma. In a near future artificial intelligence could change skin cancer screening practices through deep learning.\n                  For the sentinel lymph node, there is no interest in systematic lymphadenectomy that does not improve survival. Radiation therapy is essential for the prognosis of Merkel\u2019s carcinoma, and Mohs\u2019 surgery can be of interest. In metastatic melanoma, results on immunotherapy and targeted treatments include duration, dose, combinations, and the study of resistance mechanisms. The great novelty is immunotherapy or targeted therapy as an adjuvant treatment, giving an improvement in survival without relapse.\n               \n            ", "openaccess": "0", "openaccessArticle": false, "openaccessType": null, "openArchiveArticle": false, "openaccessSponsorName": null, "openaccessSponsorType": null, "openaccessUserLicense": null, "dcterms:subject": [{"@_fa": "true", "$": "Oncodermatologie"}, {"@_fa": "true", "$": "M\u00e9lanome"}, {"@_fa": "true", "$": "Carcinomes cutan\u00e9s"}, {"@_fa": "true", "$": "Oncodermatology"}, {"@_fa": "true", "$": "Melanoma"}, {"@_fa": "true", "$": "Non melanoma skin cancer"}], "link": [{"@href": "https://api.elsevier.com/content/article/pii/S0151963817310645", "@rel": "self", "@_fa": "true"}, {"@href": "https://www.sciencedirect.com/science/article/pii/S0151963817310645", "@rel": "scidir", "@_fa": "true"}]}, "scopus-id": "85038238732", "scopus-eid": "2-s2.0-85038238732", "pubmed-id": "29249251", "link": {"@href": "https://api.elsevier.com/content/abstract/scopus_id/85038238732", "@rel": "abstract"}, "originalText": {"xocs:doc": {"xocs:meta": {"xocs:open-access": {"xocs:oa-article-status": {"@is-open-access": "0", "@is-open-archive": "0"}}, "xocs:available-online-date": {"@yyyymmdd": "20171214", "$": "2017-12-14"}}}}}